FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US7087713B2
(en)
*
|
2000-02-25 |
2006-08-08 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
DE69927495T2
(de)
*
|
1998-05-14 |
2006-07-06 |
Coley Pharmaceutical Group, Inc., Wellesley |
Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
|
WO2000009525A2
(en)
*
|
1998-08-03 |
2000-02-24 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
ES2394458T3
(es)
*
|
1998-09-09 |
2013-01-31 |
Genzyme Corporation |
Metilación de vectores plasmídicos
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
JP2003515525A
(ja)
*
|
1999-04-06 |
2003-05-07 |
イースト カロライナ ユニバーシティ |
気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
AU783745B2
(en)
*
|
1999-08-13 |
2005-12-01 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
AU779978B2
(en)
*
|
1999-10-07 |
2005-02-24 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
WO2001051500A1
(en)
|
2000-01-14 |
2001-07-19 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
PL209127B1
(pl)
|
2000-02-23 |
2011-07-29 |
Smithkline Beecham Biolog |
Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
DE60134134D1
(de)
|
2000-05-19 |
2008-07-03 |
Corixa Corp |
Prophylaktische und therapeutische behandlung von ten mit verbindungen, die auf monosacchariden basieren
|
DK2133100T3
(da)
|
2000-06-20 |
2012-01-23 |
Corixa Corp |
MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
|
EP1961819A3
(en)
|
2000-06-28 |
2008-11-12 |
Corixa Corporation |
Composition and methods for the therapy and diagnosis of lung cancer
|
JP2004509970A
(ja)
*
|
2000-09-26 |
2004-04-02 |
ハイブリドン・インコーポレイテッド |
位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
|
ATE398175T1
(de)
*
|
2000-12-08 |
2008-07-15 |
Coley Pharmaceuticals Gmbh |
Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
PT1404873E
(pt)
|
2001-06-21 |
2013-07-30 |
Dynavax Tech Corp |
Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
PT1567641E
(pt)
|
2001-08-24 |
2012-08-21 |
Uvic Industry Partnerships Inc |
Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata
|
EP2322626A1
(en)
|
2001-09-20 |
2011-05-18 |
Glaxo Group Limited |
HIV-GAG codon-optimised DNA vaccines
|
US7514414B2
(en)
|
2001-09-24 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Suppressors of CpG oligonucleotides and methods of use
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
ATE554169T1
(de)
*
|
2001-11-02 |
2012-05-15 |
Giuliani Int Ltd |
Smad7-inhibitoren zur behandlung von krankheiten des zns
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
CA2474709A1
(en)
*
|
2002-02-04 |
2003-08-14 |
Biomira, Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
WO2003070187A2
(en)
|
2002-02-15 |
2003-08-28 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
EP1575504A4
(en)
|
2002-08-01 |
2009-11-04 |
Us Gov Health & Human Serv |
METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
PL220536B1
(pl)
|
2003-01-06 |
2015-11-30 |
Corixa Corp |
Związek aminoalkiloglukozaminidofosforanowy
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
US20040235770A1
(en)
*
|
2003-04-02 |
2004-11-25 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
|
US8188254B2
(en)
*
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
CN1989439B
(zh)
|
2004-05-06 |
2010-12-29 |
美国政府健康及人类服务部 |
治疗葡萄膜炎的方法以及组合物
|
WO2006031264A2
(en)
|
2004-05-25 |
2006-03-23 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
EP2386314A1
(en)
|
2005-03-31 |
2011-11-16 |
GlaxoSmithKline Biologicals SA |
Vaccines against chlamydial infection
|
PT2426141E
(pt)
|
2005-04-29 |
2014-11-25 |
Glaxosmithkline Biolog Sa |
Método para prevenção ou tratamento de uma infecção por m. tuberculosis
|
ATE502954T1
(de)
|
2005-06-14 |
2011-04-15 |
Protox Therapeutics Inc |
Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
MX351247B
(es)
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
TW200908994A
(en)
*
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2170384B1
(en)
|
2007-07-02 |
2016-04-13 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
EP2222710B8
(en)
|
2007-12-24 |
2016-10-12 |
ID Biomedical Corporation of Quebec |
Recombinant rsv antigens
|
EP2278979A4
(en)
|
2008-05-21 |
2012-09-26 |
Us Gov Health & Human Serv |
PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODESOXYNUCLEOTIDES
|
MX2011005915A
(es)
|
2008-12-03 |
2011-08-17 |
Proyecto Biomedicina Cima Sl |
Uso de modulinas solubles en fenol para el desarrollo de vacunas.
|
HUE028085T2
(en)
|
2009-06-24 |
2016-11-28 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV antigens
|
KR20120093811A
(ko)
|
2009-06-24 |
2012-08-23 |
아이디 바이오메디컬 코포레이션 오브 퀘벡 |
백신
|
LT3178490T
(lt)
|
2009-07-15 |
2022-07-25 |
Glaxosmithkline Biologicals S.A. |
Rsv f baltymų kompozicijos ir jų gamybos būdai
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
BR112012026227A2
(pt)
|
2010-04-13 |
2020-08-04 |
Celldex Therapeutics, Inc. |
anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
JP2015525784A
(ja)
|
2012-08-03 |
2015-09-07 |
インフェクティアス ディジーズ リサーチ インスティチュート |
活動性結核菌感染を治療するための組成物及び方法
|
SG11201500573RA
(en)
|
2012-08-06 |
2015-02-27 |
Glaxosmithkline Biolog Sa |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
WO2014140166A2
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
KR20160040290A
(ko)
|
2013-08-05 |
2016-04-12 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
조합 면역원성 조성물
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
ES2881346T3
(es)
|
2014-12-19 |
2021-11-29 |
Regenesance B V |
Anticuerpos que se unen a C6 humano y usos de los mismos
|
JP6647315B2
(ja)
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
US10813993B2
(en)
|
2015-03-03 |
2020-10-27 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
RU2017140856A
(ru)
|
2015-05-26 |
2019-06-26 |
Огайо Стейт Инновейшн Фаундейшн |
Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
CA3021328A1
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
WO2017205225A2
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
EP3735984A1
(en)
|
2016-05-27 |
2020-11-11 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
KR102595238B1
(ko)
|
2017-04-19 |
2023-10-26 |
인스티튜트 포 리서치 인 바이오메드슨 |
말라리아원충 종충에 결합하는 신규한 말라리아 백신 및 항체.
|
CA3067224A1
(en)
|
2017-06-15 |
2018-12-20 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
KR20200085302A
(ko)
|
2017-11-03 |
2020-07-14 |
다케다 백신즈 인코포레이티드 |
지카 백신 및 면역원성 조성물 및 이의 사용 방법
|
CN111836639A
(zh)
|
2018-01-26 |
2020-10-27 |
河谷细胞有限公司 |
用于联合癌症疫苗和免疫辅助疗法的组合物和方法
|
CA3094816A1
(en)
|
2018-03-22 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
US20230310323A1
(en)
|
2020-09-04 |
2023-10-05 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
BR112023020303A2
(pt)
|
2021-04-09 |
2023-11-14 |
Celldex Therapeutics Inc |
Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|